Amiodarone is a potent antiarrhythmic agent that is effective in controlling both atrial and ventricular arrhythmias. Recently, intravenous administration was demonstrated to be effective in the acute management of rhythm disorders and, in addition, appeared to shorten the loading period normally required for oral drug administration. This investigation examined the hemodynamic effects of amiodarone after both acute intravenous bolus and continuous intravenous administration. Patients with a left ventricular ejection fraction greater than 0.35 experienced improved cardiac performAmiodarone, a type III antiarrhythmic agent, has been demonstrated to be highly effective in the management of chronic refractory atrial and ventricular arrhythmias . The drug's uniquely prolonged half-life of 28 days (1) results in convenient long-term drug maintenance , but the lengthy initial oral drug loading limits its usefulness in long-term arrhythmia management and also necessitates lengthy and costly hospitalization. Intravenous amiodarone has recently been demonstrated (2,3) to be acutely effective in controlling refractory arrhythmias. Intravenous administration of amiodarone could potentially shorten the loading period duration and extend the drug's indications to include the management of patients in acutely unstable condition, assuming the drug is hemodynamically weIl tolerated. This study examine s the hemodynamic effect s of intravenous amiodarone in a broad spectrum of patients , including those with significantly compromised left ventricular function after both acute intravenous bolus administration and 3 to 5 days of continuous intravenous infusion. © 1984 by the American College of Cardiology ance due to both acute and chronic peripheral vasodilation. However, patients with a lower ejection fraction developed a 20% decrease in cardiac index and clinically significant elevation of right heart pressures after acute bolus administration; these changes were variably compensated for by peripheral vasodilation when the drug was administered intravenously over 3 to 5 days continuously. Therefore, intravenous amiodarone can result in significant impairment of left ventricular performance in patients with preexisting left ventricular dysfunction.
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Methods
Study patients. The study group comprised 12 patients with drug-resistant arrhythmias (I patient with atrial flutter and 11 patients with ventricular tachycardia or ventricular fibrillation). All patients signed a written consent form that had been approved by the Investigational Review Board of the New England Deaconess Hospital.
Among the 12 patients (10 men and 2 women), 1 had mitral valve prolapse, presyncope and long runs (> 30 beats) of nonsustained ventricular tachycardia; 1 had idiopathic dilated cardiomyopathy, presyncope and nonsustained ventricular tachycardia; 1 had recurrent atrial flutter and 9 had coronary artery disease, including 6 with sustained ventricular tachycardia and 3 with ventricular fibrillation. In all 12 patients, at least two standard antiarrhythmic agents had failed to control the arrhythmia as assessed by either clinical recurrence or persistence of electrophysiologic induction of arrhythmia despite adequate drug serum levels .
Protocol. All patients underwent fluoroscopic-guided right heart catheterization using balloon-tipped catheters with measurement of pulmonary capillary wedge , pulmonar y artery , right ventricular and right atrial pressures . Hewlett-Packard strain gauge s were zeroed at the level of one-half the anteroposterior chest wall diameter. Cardiac output was determined by the Fick method using measured oxygen consumption. Radionuclide left ventricular ejection fraction was measured by gated blood pool scan in the left anterior oblique projection in all patients. Arterial pressure 0735-1097/84/$3 .00 INTRAVENOUS AMIODARONE lACC Vol. 4, No.3 September 1984:565-70 was measured using a mercury sphygmomanometer, with mean arterial pressure being one-third the diastolic and systolic measurements.
Fifteen minutes after instrumentation, a single set of control measurements were obtained followed by an intravenous bolus injection of amiodarone (Cordarone), 300 mg, which was administered over 5 minutes. Repeat right heart pressures, oxygen consumption, radionuclide-determined left ventricular ejection fraction and arterial pressures were measured. Patients then received a continuous intravenous infusion of amiodarone, 1,000 mg, over 24 hours for 3 to 5 days, with subsequent repeat measurement of right heart pressures, oxygen consumption, radionuclide left ventricular ejection fraction and arterial blood pressure. All reasonable attempts were made to maintain cardiac medications unchanged during the infusion period with adjustments in diuretic requirements being dictated only by marked changes in clinical hemodynamic status. After intravenous administration of amiodarone, long-term oral amiodarone maintenance therapy was instituted in all patients.
All data were analyzed statistically using the paired Student's t test.
Results
Hemodynamic profile ( Table 1 ). The study patients were separated into two groups consisting of those with a left ventricular ejection fraction at rest greater than 0.35 (group A, n = 4) and those with an ejection fraction less than 0.35 (group B, n = 8). No patient had hemodynamically significant mitral regurgitation. The mean ejection fraction for group A was 0.60, whereas the mean ejection fraction for group B was 0.19. As expected, the patients in group B had higher rest pulmonary capillary wedge (13 versus 4 mm Hg) and mean pulmonary artery pressures (24 versus 10 mm Hg). The rest cardiac index was 2.1 liter/ min per rrr' in group Band 2.4 liters/min per rrr' in group A.
Hemodynamic response to intravenous amiodarone. Group A (Table 1) . After acute bolus administration of 300 mg amiodarone, cardiac index increased from 2.4 to 2.7 liters/min per rrr' and was associated with a decrease in systemic vascular resistance from 1,721 to 1,1419 dynes . s . em -5. Despite the increase in forward cardiac output, pulmonary capillary wedge pressure increased from 4 to 8 mm Hg and mean pulmonary artery pressure increased from 10 to 17 mm Hg. No significant change was noted in either radionuclide left ventricular ejection fraction or heart rate after bolus administration.
Continuous intravenous amiodarone administration for 3 to 5 days resulted in a further augmentation of cardiac index to 3.4 liters/min per m 2 and a further reduction in systemic vascular resistance to I, 135 dynes-s-cm-5 ( Figure  I ). Unlike acute administration, chronic intravenous therapy resulted in a return of both pulmonary capillary wedge and mean pulmonary artery pressures to control values. No significant change in radionuclide left ventricular ejection fracture, heart rate or right atrial pressure occurred with chronic therapy.
Group B (Table 1) . Intravenous bolus administration of 300 mg amiodarone resulted in a significant decrease in cardiac index from 2.1 to 1.7 liters/min per m 2 . Despite a significant decrease in mean arterial pressure, overall systemic vascular resistance increased from 2,040 to 2, 204 dynes-s-cm -5. Mean pulmonary artery pressure increased significantly after acute drug administration (24 to 35 mm Hg). Although pulmonary capillary wedge pressure increased from 13 to 20 mm Hg, this did not reach statistical significance. Radionuclide left ventricular ejection fraction and heart rate did not change significantly after drug administration.
After No patients in group A experienced an adverse effect during either acute or chronic amiodarone infusion. However, five of eight patients in group B experienced clinically significant hemodynamic deterioration with intravenous amiodarone. Patient 9 developed hypotension secondary to decreased cardiac output after the 300 mg bolus infusion. The hypotension resolved within 15 minutes with the use oflow doses of dopamine. The patient subsequently received chronic intravenous amiodarone infusions without adverse sequelae. Patient 10 developed moderate hypotension after the intravenous bolus administration and then progressively developed pulmonary edema after 36 hours of continuous intravenous infusion that required combined dopamine and diuretic drugs for stabilization. The intravenous infusion was discontinued and the patient was subsequently treated with oral amiodarone (1,000 mg orally for 14 days) without further incident. Patient 12 developed marked systemic hypotension and elevation of right heart pressures because of decreased cardiac output that responded to dopamine infusion. He then experienced a "flush" reaction to the drug and intravenous therapy was abandoned. The other two patients (Cases 5 and 7) both developed marked pulmonary congestion while receiving continuous amiodarone infusion.
In both patients, the congestive heart failure was treated with vigorous diuresis and the infusion was continued for (1, (4) (5) (6) (7) (8) (9) have demonstrated clinical suppression of refractory arrhythmias by amiodarone in 60 to 90% of patients studied . Although the drug was initially considered to have few side effects (4, 8) , more recent reports (9-11) have demonstrated significant problems , with the most worrisome being pulmonary infiltrates, neurologic abnormalities, skin discoloration and thyroid disturbances. Exacerbation of congestive heart failure has been relatively infrequent with the oral preparation, but the extremely long half-life of 15 to 30 days has limited the utility of sequential hemodynamic measurements to accurately assess its hemodynamic effects.
Preliminary studies (4) have suggested that intravenous amiodarone results in a rapid antiarrhythmic effect which lasts from 20 minutes to 4 hours and which can be utilized to control refractory ventricular arrhythmias. Several investigators (12) (13) (14) have collectively reported selective reversion of ventricular tachycardia to sinus rhythm with intravenous amiodarone in 11 patients without significant side effects.
Morady et al. (3) confirmed the therapeutic effectiveness of intravenous amiodarone in 12 of 15 patients with ventricular tachycardia refractory to at least two conventional antiarrhythmic drugs . Control was obtained within 12 hours in all successfully treated patients and intravenous usage did not result in exacerbation of congestive heart failure in any patient despite a group mean ejection fraction of 0.30 .
Adverse hemodynamic effects. Although intravenous amiodarone has major value as an antiarrhythmic agent to control acute life-threatening arrhythmias, it has also been reported to have significant side effects. Both hypotension and cardiac collapse are the major complications reported with intravenous usage. Benaim and Uzan (12) reported that five of their patients after intravenous amiodarone administration experienced cardiovascular collapse and required vasopressor agents. Michat et al. (14) noted a mean decrease in blood pressure of 15 mm Hg in 6 of 20 patients , although no severe complications ensued . Installe et al. (15) administered intravenous amiodarone to 95 patients with arrhythmia after cardiac operation s. Seventeen patients ( 18%) experienced an average decrease in mean arterial pressure of 15 mm Hg and five patients with marked cardiomegaly developed cardiogenic shock requiring vasopressors and intraaortic balloon pulsation . Lastly, 11 cases of adverse effects of intravenous amiodarone were reported to the French Society of Cardiology (16) , including five deaths after bolus administration to patients with significant left ventricular dysfunction.
Therefore, adverse hemodyn amic effects of intravenous amiodarone appear to represent the major complication limiting its clinical usefulness. Singh ct al. (17) examined the effects of amiodarone on cardiac and coronary hemody- -----. . . . . . . . . . . . . . . . . . . . 1 --. ... Acute and chronic hemodynamic effects in the study patients. Our 12 patients with refractory arrhythmias manifested greater left ventricular dysfunction, with 8 of the 12 having a left ventricular ejection fraction less than 0.35 . The hemodynamic effects of intravenou s amiodarone were determ ined immediatel y after intravenous bolus administration and also after chronic (3 to 5 days) infusion. Patients with good left ventricular function (group A) (Fig. l A) exhibited an increase in cardiac index and a decrease in systemic vascular resistance after both acute and chronic admin istration consistent with the drug ' s known potent vasodilator properties. Of note is the mild increase in both pulmonary capillary wedge and mean pulmonary artery pressures, possibly reflecting a mild negative inotropic effect that is compensated for chronically by further systemic vasodilation. The response of patients in group B (left ventricular ejection fraction <0.35) to acute and chronic intravenous amiodarone was quite different (Fig. IB) . A 20% reduction in cardiac index occurred with bolus injection and was associated with an increase in mean pulmonary artery pressure and systemic vascular resistance . This is consistent with a negative inotropic effect which reduces cardiac output and mean arterial pressure , resulting in activation of sympathetic peripheral vasoconstriction and , hence, negating the inherent peripheral vasodilation of the drug. After chronic intravenous therapy, there was a gradual return to control values which is due to a decrea se in the systemic vascular resistance . Continuous infusion results in more pronounced systemic vasodilation, which is able to compensate for the negative inotropic effect. The hemodynamic effects are due to the drug alone since the diluent (Tween 80) has no known hemodynamic effect.
·
Intravenous amiodarone posse sses both negative inotropic and peripheral vasodilatory properties. In patients with good left ventricular function, the negative inotropic properties are minimal because of the intrinsic cardiac contractil e reserve. However, patients with moderately impaired left ventricular function are much more vulnerable to the adverse contractile effects . The clinical potential of this adverse effect on left ventricular performance is highlighted by five of the eight patients with left ventricular ejection fraction less than 0 .35 who developed a major clinical deterioration consisting of either marked hypotension (three patients) or severe worsening of left heart failure (two patients). The deterioration occurred during bolus administration in two patients and during continuous infusion in three patients .
A more gradual intravenous administration of amiodarone may have avoided the acute hypotension seen with bolus administration, but presumably it would not avoid the exacerbation of left ventricular failure which occurred in three patients receiving a constant intravenous infusion. Despite the adverse hemodynamic effects, all rut two patients were continued on intravenous therapy by increasing diuretic dosage. Two patients developed hypotension and pulmonary edema that did not respond promptly to vasopres sors and necessitated discontinuation of intravenous drug therap y.
All patients have received long-term oral therap y without significant adverse hemod ynamic effects. The experience that oral amiodarone is well tolerated in patients with severe left ventricu 'ar dysfunction , whereas intravenous medication is not, possibly reflects the higher serum levels obtained with intravenous administration.
Clinical implications. The following clinical recommendations are warranted: 1) intravenous amiodarone results in both negative inotropi c and peripheral vasodilatory effects; 2) intravenous amiodarone should be reserved as a second or third line antiarrhythmic agent in patients with moderate left ventricular dysfunction because of its adverse hemodynamic effects; 3) careful hemodynamic monitoring is warranted in patients with impa ired left ventricular function who are receiving intravenous amiodarone; and 4) rapid intravenous bolus admini stration of amiodarone is rarely appropriate , and a more gradual intravenous load over 30 to 60 minutes may avoid the hypoten sion of the 5 minute injection ; and 5) those patient s with chronic ventricular arrhythmias are best treated with the safer, albeit longer , method of high dose oral loading .
